N4 Pharma, established in 2014, is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle, Nuvec®, has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
Find out more about N4 Pharma on their website.
